F-1/A: Charming Medical Amends IPO Filing, Adds Auditor Consent

Charming Medical Limited filed Amendment No. 3 to its F-1 registration statement, primarily to include the consent of its independent registered public accounting firm, WWC, P.C.

Summary

• Amendment No. 3 to Form F-1 (File No. 333-287258) was filed by Charming Medical Limited on September 10, 2025.
• The primary purpose of this amendment is to file Exhibit 23.1, which is the Consent of WWC, P.C., Independent Registered Public Accounting Firm, and to amend and restate the exhibit index.
• This Amendment No. 3 explicitly states that it does not modify any provision of the prospectus that forms a part of the Registration Statement.
• The company is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933.
• Indemnification provisions for directors and officers are detailed, allowing for indemnification against expenses, judgments, fines, and settlement amounts in legal, administrative, or investigative proceedings, provided the person acted honestly and in good faith.
• On September 19, 2024, Ms. Kit Wong, director and sole shareholder, transferred 1,725 shares, representing 19.40% of issued shares, to five shareholders.
• On November 1, 2024, Ms. Wong transferred 400,140 Class A Ordinary Shares, representing 3% of issued Class A Ordinary Shares, to a pre-IPO investor for a consideration of US$1,300,000.
• On October 18, 2024, a 1-to-1,500 share split was approved, changing the company's authorized shares to 75,000,000 (60,000,000 Class A and 15,000,000 Class B), each with a par value of US$0.0001.
• On November 1, 2024, 2,000,000 Class B ordinary shares with a par value of US$0.0001 each were allotted and issued to Ms. Wong.
• The company undertakes to file post-effective amendments for prospectus updates, fundamental changes, and material distribution plan information, and to remove unsold securities from registration.

Sentiment

Score: 5

Explanation: The filing is an administrative amendment, primarily focused on procedural requirements like auditor consent and updating the exhibit index. It does not contain new substantive financial or operational information that would significantly alter the company's perceived value or prospects. The explicit delay of the effective date is a minor negative, but expected for an ongoing registration process, leading to a neutral sentiment.

Positives

• The inclusion of the auditor's consent (WWC, P.C.) is a necessary procedural step for the IPO registration to progress towards effectiveness.
• Detailed indemnification provisions for directors and officers may help attract and retain qualified individuals, enhancing corporate governance.

Negatives

• The effective date of the registration statement is explicitly delayed until a further amendment is filed, indicating the IPO process is not yet complete.

Risks

• Indemnification for liabilities arising under the Securities Act of 1933 may be deemed against public policy by the SEC and therefore unenforceable.
• The company, its officers, and directors face potential liabilities under the Securities Act of 1933 related to the offering.
• The company is required to file post-effective amendments to reflect fundamental changes, update financial statements, or include material information regarding the plan of distribution, which could introduce new disclosures or delays.

Future Outlook

The proposed sale to the public is anticipated as soon as practicable after the effective date of the Registration Statement. However, the effective date is currently delayed until a further amendment is filed that specifically states the registration statement shall become effective.

Management Comments

• Kit Wong signed the registration statement as Chief Executive Officer, Director, and Chairman of the Board.
• Ching Man Cheung signed the registration statement as Chief Financial Officer.

Industry Context

This administrative amendment is a standard procedural step in the IPO process for a company in the medical sector, indicating progression towards a public listing. It does not provide specific industry-related insights or trends.

Corporate Governance

Legal Proceedings

• The indemnification provisions cover potential 'legal, administrative or investigative proceedings,' indicating the company acknowledges the possibility of such matters, though no specific current proceedings are disclosed.
• The filing notes that indemnification for liabilities arising under the Securities Act of 1933 may be against public policy as expressed in the Act and therefore unenforceable, implying potential legal challenges if such indemnification is sought.

Related Party Transactions

• On September 19, 2024, Ms. Kit Wong (director and sole shareholder) transferred 1,725 shares (19.40%) to five shareholders.
• On November 1, 2024, Ms. Wong transferred 400,140 Class A Ordinary Shares (3%) to a pre-IPO investor for US$1,300,000.
• On November 1, 2024, 2,000,000 Class B ordinary shares were allotted and issued to Ms. Wong.

Stakeholder Impact

• Shareholders: Existing shareholders' ownership percentages were affected by the share split and transfers. Future shareholders will be subject to the outlined indemnification policies and the risks associated with the offering.
• Directors and Officers: Benefit from the detailed indemnification provisions, which may reduce personal liability exposure, but remain subject to liabilities under the Securities Act.
• Pre-IPO Investor: Acquired a significant stake in the company at a specific valuation prior to the public offering.

Next Steps

• File a further amendment to specifically state that the registration statement shall become effective.
• Proceed with the proposed sale to the public as soon as practicable after the effective date.
• File post-effective amendments as required to include any prospectus updates, reflect fundamental changes, or disclose material information regarding the plan of distribution.

Key Dates

Recommendation

This filing is an administrative update to an ongoing IPO registration, primarily adding auditor consent and detailing past share transactions and corporate governance policies. It does not provide new financial or operational data that would warrant a 'buy' or 'sell' recommendation. Investors should 'hold' pending the full prospectus and pricing of the IPO to make an informed decision based on comprehensive financial and strategic details.

Keywords

Charming Medical, F-1/A, SEC filing, IPO, registration statement, auditor consent, share split, private placement, corporate governance, indemnification, British Virgin Islands, medical